Combination of temsirolimus with cisplatin as anti-cancer agents through inducing apoptosis and altering cell cycle distribution in Hela cell line

Qian Shao; Dongxian He

doi:10.54097/hset.v65i.11360

Authors

Qian Shao
Dongxian He

DOI:

https://doi.org/10.54097/hset.v65i.11360

Keywords:

Temsirolimus, Cisplatin, Cervical cancer, mTOR pathway, Apoptosis, Cell cycle distribution.

Abstract

Combination treatment is the most effective therapy strategy on cancer by dramatically reducing drug toxicity and enhancing efficacy. In this study, we assessed whether temsirolimus, an mTOR inhibitor enhanced anti-cancer effects of cisplatin on human cervical Hela cell line or not. The combination of temsirolimus and cisplatin, to a large extent, reduced proliferation rate of cervical Hela cells in comparision with single chemotherapeutics cisplatin in vitro and resulted in synergistic effects (CI<1). Flow cytometry results indicated that temsirolimus markedly increased cisplatin-induced apoptosis. Thus, the combination chemotherapy using cisplatin and temsirolimus could be a novel strategy for synergistic effects against human cervical cancer.

Downloads

Download data is not yet available.

References

Eifel PJ. Chemoradiotherapy in the treatment of cervical cancer. Semin Radiat Oncol. 2006;16:177-85.

Bae-Jump VL, Zhou CX, Boggess JF, Gehrig PA. Synergistic Effect of Rapamycin and Cisplatin in Endometrial Cancer Cells. Cancer-Am Cancer Soc. 2009;115:3887-96.

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New Engl J Med. 2007;356:2271-81.

Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265-79.

Weiss RH. P21 (Waf1/Cip1) as a therapeutic target in breast and other cancers. Cancer Cell. 2003;4:425-9.

Kamata S, Kishimoto T, Kobayashi S, Miyazaki M, Ishikura H. Possible involvement of persistent activity of the mammalian target of rapamycin pathway in the cisplatin resistance of AFP-producing gastric cancer cells. Cancer Biol Ther. 2007;6:1036-43.

Tam KH, Yang ZF, Lau CK, Lam CT, Pang RWC, Poon RTP. Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Lett. 2009;273:201-9.

Hou GQ, Zhang Q, Wang LL, Liu MY, Wang JR, Xue LX. mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice. Cancer Lett. 2010;290:248-54.

Shafer A, Zhou CX, Gehrig PA, Boggess JF, Bae-Jump VL. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. Int J Cancer. 2010;126:1144-54.

Itamochi H, Oishi T, Shimada M, Sato S, Uegaki K, Naniwa J, et al. Inhibiting the mTOR Pathway Synergistically Enhances Cytotoxicity in Ovarian Cancer Cells Induced by Etoposide through Upregulation of c-Jun. Clin Cancer Res. 2011;17:4742-50.

Hoda MA, Mohamed A, Ghanim B, Filipits M, Hegedus B, Tamura M, et al. Temsirolimus Inhibits Malignant Pleural Mesothelioma Growth In Vitro and In Vivo Synergism with Chemotherapy. J Thorac Oncol. 2011;6:852-63.